Monitor for enrollment updates and eventual Phase 2 data readout from the DReAMzz study, which will inform Phase III design. The Fast Track designation supports potential expedited regulatory review but does not guarantee approval. Cash runway and dilution risk remain key overhangs for this micro-cap biotech.
Price Chart
Executive Summary
Incannex Healthcare announced commencement of participant screening in its DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea. The study builds on prior positive Phase 2 data showing up to 83% AHI reduction, and IHL-42X holds FDA Fast Track designation. This is a routine operational milestone for a clinical-stage biotech with no financial data in the filing.
Key Facts
- Participant screening commenced in DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea
- IHL-42X has FDA Fast Track designation
- Prior Phase 2 data showed up to 83% reduction in Apnea-Hypopnea Index (AHI) vs placebo
- First tranche of clinical sites approved; additional sites expected to follow
- No FDA-approved oral pharmaceutical therapies currently available for OSA
Financial Impact
No financial data provided in the filing; clinical-stage company with no revenue
Risk Factors
- Clinical trial risks: enrollment delays, safety/efficacy issues, or failure to meet endpoints
- Cash burn and potential need for dilutive financing given $38M market cap and no revenue
- Regulatory risk: Fast Track does not guarantee approval; Phase III still required
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-080622 |
| Document: ea029867401ex99-1.htm | 0001213900-26-080622 |
| Document: 0001213900-26-080622-index-headers.html | 0001213900-26-080622 |
| Document: 0001213900-26-080622-index.html | 0001213900-26-080622 |
| Document: 0001213900-26-080622.txt | 0001213900-26-080622 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.62 (−18.89%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.62 (−30.13%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.62 (−18.13%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.62 (−17.09%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.62 (−17.09%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.62 (−32.99%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.62 (−32.99%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.62 (−28.61%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.62 (−32.47%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.62 (−32.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers